Author

Diego A. Pedroza

Baylor College of MedicineORCID 0000-0002-7355-2952Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

Alex J. SmithiD· 4 shared Fengshuo LiuiD· 4 shared Jeffrey M. RoseniD· 4 shared Na ZhaoiD· 4 shared Sebastian J. CalderoniD· 4 shared Hilda L. ChaniD· 3 shared Xiang H.-F. ZhangiD· 3 shared Xueying YuaniD· 3 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Alex J. SmithORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity

Yang Gao, Emmanuel Anning, Linhua Wang, Yating Cheng, Ling Wu, Jun Wang, Fengshuo Liu, Zhan Xu, Xiaoxin Hao, Jun Liu, Liqun Yu, Yunfeng Ding, Weijie Zhang, David Glenn Edwards, Yi-Hsuan Wu, , Xiang H.-F. Zhang

This study identifies an early neutrophil interferon program that predicts resistance to anti-PD1 therapy and limits durable anti-tumor immunity.

bioRxiv · Oct 1, 2026 · PreprintCancer Biology

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer

Alex J. Smith, Zachary Schrank, Nan Guan, Diego A. Pedroza, Sebastian J. Calderon, Xueying Yuan, Na Zhao, Zoe Gabriel, Yang Gao, Charlotte Helena Rivas, Fengshuo Liu, Jonathan Stuart Serody, Charles M. Perou, Henry Shelton Earp, Jeffrey M. Rosen

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

Cancer Immunology Research · Aug 17, 2026Peer-reviewedCancer Biology

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers

Diego A. Pedroza, Xueying Yuan, Fengshuo Liu, Hilda L. Chan, C. Zhang, William Bowie, Alex J. Smith, Sebastian J. Calderon, Nadia Lieu, Weiguo Wu, Paul Porter, Poonam Sarkar, Na Zhao, Constanze V. Oehler, Ondrej Peller, , Jeffrey M. Rosen

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

Nature Communications · Jan 3, 2026Peer-reviewedCancer Biology

CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC

Xueying Yuan, Xiaoxin Hao, Hilda L. Chan, Na Zhao, Diego A. Pedroza, Fengshuo Liu, Kang Le, Alex J. Smith, Sebastian J. Calderon, Nadia Lieu, Michael Soth, PHILIP G. JONES, Xiang H.-F. Zhang, Jeffrey M. Rosen

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.

JCI Insight · Sep 17, 2024Peer-reviewedCancer Biology